drugset

drugset / Trial / NCT02391272

A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy

NCT02391272 ↗

Phase 3 Completed 31 enrolled Shandong University Institute of Hematology & Blood Diseases Hospital, China · collab Southern Medical University, China · collab The Affiliated Hospital of Qingdao University · collab The Second Hospital of Hebei Medical University · collab

NaSingle-groupOpen-labelTreatment

Summary

The project was undertaking by Qilu Hospital of Shandong University and other well-known hospitals in China. Aims at evaluating efficacy and safety of rhTPO in management of ITP in pregnancy.

Timeline

Start: 2015-03
Primary completion: 2015-11
Completion: 2016-06

Publications

Kong Z, Qin P, Xiao S, Zhou H, Li H, Yang R, Liu X, Luo J, Li Z, Ji G, Cui Z, Bai Y, Wu Y, Shao L, Peng J, Ma J, Hou M. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 2017 Aug 31;130(9):1097-1103. doi: 10.1182/blood-2017-01-761262. Epub 2017 Jun 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	recombinant human thrombopoietin	Protein / enzyme biologic	300 iu/kg	Intravenous

Indications